Document Detail


Effects of celecoxib on volumes of hematoma and edema in patients with primary intracerebral hemorrhage.
MedLine Citation:
PMID:  19168192     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Celecoxib is a potent anti-inflammatory drug with a safety profile that has been well-demonstrated in several human diseases and is reported to have beneficial effects in a rat model of intracerebral hemorrhage (ICH). We investigated the efficacy and safety of celecoxib treatment in patients with primary ICH. We retrospectively collected clinical data of patients admitted within 48 h after the onset of primary ICH. We classified the patients administered celecoxib (400 mg/day) for > or =7 days as the celecoxib-treated group (n=17) and classified the patients who were not administered celecoxib as the control group (n=17). The volumes of hematoma and edema were analyzed with initial and follow-up (at approximately 7 days) brain CT scans. Baseline characteristics, initial severity of neurologic sequelae, and initial volumes of the lesions were not different between the groups. Celecoxib treatment significantly reduced the volumes of edema noted on follow-up brain CT scans as compared with the volumes in the control group (30.2+/-17.7 vs. 55.5+/-40.6 mL, p=0.027) and also reduced the ratio of initial hematoma and edema volumes vs. the follow-up volumes as compared with those of the control group (hematoma, 0.90+/-0.29 vs. 1.54+/-1.12, p=0.035; edema, 0.95+/-0.32 vs. 2.08+/-0.88, p<0.001). The incidences of adverse events during the admission were not different between the groups. These results suggest that celecoxib may be safe and efficacious in patients with primary ICH. To confirm this notion, a large-sized prospective study should be performed.
Authors:
Hee-Kwon Park; Seung-Hoon Lee; Kon Chu; Jae-Kyu Roh
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-01-24
Journal Detail:
Title:  Journal of the neurological sciences     Volume:  279     ISSN:  1878-5883     ISO Abbreviation:  J. Neurol. Sci.     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-03-03     Completed Date:  2009-07-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375403     Medline TA:  J Neurol Sci     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  43-6     Citation Subset:  IM    
Affiliation:
Department of Neurology, Seoul National University Hospital, Seoul, South Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anti-Inflammatory Agents, Non-Steroidal / adverse effects,  therapeutic use*
Brain Edema / drug therapy*,  pathology
Cerebral Hemorrhage / drug therapy*,  pathology
Female
Hematoma / drug therapy*,  pathology
Humans
Male
Middle Aged
Pyrazoles / adverse effects,  therapeutic use*
Retrospective Studies
Sulfonamides / adverse effects,  therapeutic use*
Tomography, X-Ray Computed
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Pyrazoles; 0/Sulfonamides; 169590-42-5/celecoxib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren's syndro...
Next Document:  [Cheek paraganglioma: a rare location].